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abstract
PURPOSE Raising awareness of colorectal cancer (CRC) symptoms for early recognition, reduction of modiﬁable
risk factors, and removing barriers to seeking medical help could lower its mortality. This study aimed to assess
the level of public awareness of CRC in the Gaza Strip.
MATERIALS AND METHODS This was a cross-sectional study conducted at three hospitals and 10 high schools
between September and October 2017. The Arabic version of the validated Bowel Cancer Awareness Measure
(BoCAM) questionnaire was used to evaluate awareness of CRC symptoms and risk factors, and barriers to
seeking medical help. Adults (age ≥ 18 years) in three major hospitals and adolescents (ages 15 to 17 years) in
10 schools were recruited for face-to-face interviews to complete the BoCAM.
RESULTS Of 3,172 potential participants, 3,080 completed the BoCAM (response rate, 97.1%). Among these,
1,578 (51.2%) were adults and 1,614 (52.4%) were females. Persistent abdominal pain was the most
commonly recognized CRC symptom (n = 1,899; 61.7%), whereas anorectal pain was the least common (n =
1,056; 34.3%). In total, 2,177 (70.7%) were not conﬁdent in recognizing CRC symptoms or signs. Having
a bowel disease was the most frequently recognized CRC risk factor (n = 1,456; 47.3%) and diabetes the least
recognized (n = 591; 19.2%). The overall mean scores6 standard deviations for recalling and recognizing CRC
symptoms were 1.2 6 1.3 and 4.3 6 2.3, respectively (out of 9 points). The overall mean scores 6 standard
deviations for recalling and recognizing CRC risk factors were 0.7 6 0.8 and 8.0 6 3.1, respectively (out of 16
points). Emotional barriers were the most commonly reported barriers to seeking medical help, with feeling
worried about what a doctor might ﬁnd as the most common barrier (n = 1,522; 49.4%).
CONCLUSION Public awareness of CRC is suboptimal in Gaza. Improving CRC awareness with educational
interventions is needed, including in local schools.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Globally, colorectal cancer (CRC) is the third most
common malignancy and the fourth most frequent
cause of cancer-related deaths.1 In Gaza, CRC is the
most common cancer among males, accounting for
15.5% of their cancers, and second to breast cancer
in women, accounting for 11.2% of their cancers.2
This is higher than a worldwide estimate of 10.6% of
CRC among all patients with cancer in 2018.3 It also
has incidence rates of 11.5 and 10.3 per 100,000 of
male and female populations, respectively, in Gaza
and is the second most frequent cause of cancer-
related deaths, responsible for 11.0% of total
cancer-related deaths.4 Such high mortality rates
could be a result of diagnosis at advanced stages
due to low awareness levels of CRC symptoms and
risk factors, and difﬁcult access to health care
facilities.
Greater public awareness of CRC symptoms may lead
to less delay before seeking medical advice that, in
turn, will facilitate early detection of CRC, increase
survival rates, and improve outcomes.5-7 Furthermore,
the lack of a CRC screening program in Gaza ne-
cessitates raising CRC awareness among the general
population.2
Generally, women are believed to display more health-
related behaviors than men in Palestine. However,
recent studies have shown increasing smoking rates
among female university students and higher obesity
rates among women.8,9 Moreover, a previous study on
breast cancer awareness in Gaza showed signiﬁcantly
higher awareness among adult women, compared
with adolescent females,10 despite health education
being part of the school curriculum. Exploring the
health awareness of adolescents on a variety of is-
sues is important because this might shape their
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health-related behavior in the future. In view of the high
proportion of young people in the Palestinian population,
with 39% younger than 15 years of age and 30% 15 to
29 years of age, it is an important long-term investment.11,12
Younger age groups (15 to 24 years and 25 to 34 years)
represent 2.5% and 5.2%, respectively, of the total re-
ported patients with CRC from 2009 to 2014 in Gaza.13
This study aimed to explore (1) public awareness of CRC
symptoms and risk factors in Gaza, (2) public awareness of
CRC age-related risk, (3) the potential barriers to seeking
medical help, and (4) differences between population
groups, such as men and women, as well as adults and
adolescents.
MATERIALS AND METHODS
Study Design and Population
This was a cross-sectional study conducted from Sep-
tember 1 to October 31, 2017, using the Bowel Cancer
Awareness Measure (BoCAM) questionnaire, which is
a validated measurement for public awareness of CRC.14
Awareness levels were compared among different pop-
ulation groups, such as between men and women and
between adolescents and adults. The questionnaire con-
sists of ﬁve sections: (1) demographic data; (2) evaluation
of knowledge of age-related CRC risk and conﬁdence to
detect its symptoms; (3) open-ended (recall) questions and
(4) closed (recognition) questions with a comparison be-
tween the outcomes using both recall versus recognition;
and (5) barriers to seeking medical advice. A 3-point scale,
with answers yes, no, and I do not know, was used to
evaluate the recognition of signs and symptoms of CRC, as
well as to explore barriers to seekingmedical help, that were
further categorized into emotional, practical, and service
barriers. A 5-point Likert scale was used to assess the
recognition of CRC risk factors.
The BoCAM was translated from English to Arabic and then
back-translated into English by several people proﬁcient in
both languages. Before starting data collection, a pilot study
was conducted with 92 respondents to test the clarity of the
questions of the Arabic version of BoCAM. A reliability
analysis was carried out on the perceived task values scale
comprising 29 items. Cronbach’s alpha (0.72) showed that
the questionnaire reached acceptable reliability. Although it
has not been validated, a similar questionnaire was used in
some previous studies conducted in Arabic-speaking
countries.11,15,16
Sampling Methods
Health care services in the Gaza Strip are provided by the
government, nongovernmental organizations, or private
providers. Governmental hospitals are the main entry point
for health care services in Gaza because they provide most
basic health care at no or little cost to the insured pop-
ulation.10 Health care insurance is obtainable at low cost.
Nongovernmental organization facilities often provide
specialized health care in certain areas, such as burn care
or limb reconstruction. The fees of private hospitals prohibit
most people from accessing these services. Therefore, men
and women 18 years of age or older admitted to or visiting
governmental hospitals were the target population to get
a broad representation of the general population. Patients
or visitors to oncology departments were excluded from
the study.
There are 13 governmental hospitals in Gaza.2 From
these, the largest three, located in separate geographic
locations, were chosen for recruitment of participants by
stratiﬁed sampling. This sampling area covered most of
Gaza’s population, producing a representative sample.
Parallel to this, adolescents from 10 high schools (out of
14717), located in the same areas as the study hospitals,
were recruited. High school students study health-
related topics in their curriculum, which presented the
opportunity to explore their awareness of CRC. Partici-
pants were invited for face-to-face interviews to complete
the BoCAM.
CONTEXT
Key Objective
The increasing incidence and high mortality rates of colorectal cancer (CRC) in the Gaza Strip make it an important public
health concern. Therefore, this study examined public awareness of symptoms and risk factors, as well as reported barriers
to seeking medical help and compared these between men and women, as well as adults and adolescents.
Knowledge Generated
Poor public knowledge of CRC symptoms and risk factors, as well as the other reported barriers found in this study, may play
a signiﬁcant role in the diagnosis of CRC at advanced stages because of delays before patients see the doctor, ultimately
leading to a lower survival rate.
Relevance
A systematic national education program to promote the public awareness of CRC tailored to suit all age groups is needed. In
addition, an urgent need to establish a CRC screening program to facilitate its early detection exists.
Elshami et al
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Data collectors were trained to recruit participants, dis-
tribute the questionnaires, and facilitate completion. Before
completing the questionnaire, a detailed explanation of the
study, including its purpose, was given to the participants.
Informed consent was obtained from the participants, and
ethical approval was obtained from both the Palestinian
Ministry of Health and the Ministry of Higher Education.
Statistical Analysis
Descriptive statistics were used to report the knowledge of
age-related CRC risk. One unprompted open question and
nine prompted closed questions assessed the knowledge of
CRC signs and symptoms. The unprompted question asked
participants to write down the CRC signs and symptoms
they could remember, whereas the closed questions
assessed knowledge on speciﬁc signs and symptoms.
Every correctly recalled sign/symptom or correct answer in
the closed questions (yes) was given 1 point, whereas
incorrect answers (no and I do not know) received no
points.
Another open question requested recall of CRC risk fac-
tors, and eight closed questions assessed recognition of
CRC risk factors. Every correctly recalled risk factor was
given 2 points. Answers to the eight closed questions were
scored on a 5-point Likert scale. This was converted to a 3-
point scale, because it was difﬁcult for participants to
distinguish between agree versus strongly agree and
disagree versus strongly disagree; therefore, the response
strongly agree was recoded to agree, and strongly disagree
was recoded as disagree.10 Disagree was given no points,
not sure was given 1 point, and agree was given 2 points.
Cumulative scores were calculated for recognizing CRC
signs and symptoms as well as risk factors and reported as
mean 6 standard deviation out of the total score of 9 for
signs and symptoms and 16 for risk factors. Furthermore,
10 questions were asked about barriers to seeking
medical advice that were scored yes, no, and I do not
know, and are reported as total numbers and percentages
for each point.
The variable of interest was the overall awareness mean
score for each section (signs/symptoms and risk factors),
for which the one-sample t test was used. The two-sample
t test was used to compare the total mean scores of recall
and recognition and their percentages between male and
female as well as adult and adolescent participants, which
were normally distributed. The χ2 test was used to compare
the awareness of each CRC symptom and risk factor be-
tween these two subpopulations. Multiple logistic re-
gression was used to test the association between sex and
age group with recalling CRC symptoms and risk factors. It
was also used to test their association with recognizing the
symptoms and to test the relationship between this rec-
ognition and having barriers to seeking medical advice.
Ordinal regression was used to test the association of age
group and sex with recognizing risk factors. Data were
analyzed using Stata software version 15.0 (StataCorp,
College Station, TX).
RESULTS
Characteristics of Participants
Of 3,172 invited participants, 3,080 completed the BoCAM
questionnaire (response rate, 97.1%). Among these, 1,578
(51.2%) were adults, 1,502 (48.9%) were adolescents, and
1,614 (52.4%) were females. The mean age of all partic-
ipants was 25.4 6 12.1 years.
Knowledge and Conﬁdence to Detect CRC Symptoms
A total of 442 participants (14.4%) were not conﬁdent at all
about their ability to detect a symptom of CRC, whereas
1,735 (56.3%) were not conﬁdent. Generally, awareness of
CRC signs and symptoms, as well as risk factors, was low
when recall questions were used and higher with recog-
nition questions. Abdominal pain was the most commonly
recognized CRC symptom (n = 1,899; 61.7%), whereas
anorectal pain was the least common (n = 1,056; 34.3%;
Table 1). The overall mean scores for recalling and rec-
ognizing CRC symptoms were 1.2 6 1.3 and 4.3 6 2.3,
respectively, out of 9 possible points. Adults demonstrated
higher awareness than adolescents (4.9 6 2.3 v 3.8 6 2.
0 out of 9; P , .001). This was also true after adjusting for
sex, where adults generally showed a signiﬁcantly higher
likelihood of recalling and recognizing CRC signs and
symptoms, although they were less likely to recall ab-
dominal pain (odds ratio [OR], 0.79; 95% CI, 0.69 to 0.92;
P = .002), and there were no signiﬁcant associations with
recall of anorectal pain and abdominal mass (Table 2).
Females had a signiﬁcantly higher mean score than males
(4.5 6 2.3 v 4.2 6 2.3 of 9; P , .001). However, after
adjustment for age group, there was no independent as-
sociation of sex with the recalled CRC signs and symptoms
except anorectal pain, where females had a 57% decrease
in the odds (OR, 0.43; 95% CI, 0.29 to 0.64; P , .001).
Awareness of CRC Risk Factors
Having bowel disease was the most frequently recognized
CRC risk factor (n = 1,456; 47.3%), and diabetes was the
least recognized (n = 591; 19.2%; Table 3). Only 918
participants (29.8%) gave a correct answer for CRC age-
related risk, whereas 1,391 (45.2%) believed that it was
unrelated to age. Out of 16 points, the overall mean scores
for recalling and recognizing CRC risk factors were 0.76 0.
8 and 8.0 6 3.1, respectively. Adults demonstrated better
recognition of every risk factor and a higher overall score
compared with adolescents (8.7 6 3.2 v 7.3 6 2.8 of 16;
P , .001). This was also evident after adjusting for sex,
except for doing less physical activity, which did not have an
association with age group. Females also had signiﬁcantly
higher awareness than males (8.36 3.0 v 7.86 3.2 of 16;
P , .001). However, after adjustment for age group, fe-
males had signiﬁcantly lower odds of recalling eating red
or processed meat once a day or more (OR, 0.62; 95% CI,
Public Awareness of Colorectal Cancer in the Gaza Strip
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0.48 to 0.79; P , .001) and having bowel disease (OR, 0.
69; 95% CI, 0.52 to 0.92; P = .010; Table 4). In contrast,
females had signiﬁcantly higher odds of recognizing ﬁber-
free diet (OR, 1.55; 95% CI, 1.36 to 1.76; P, .001), having
a relative with CRC (OR, 1.42; 95% CI, 1.25 to 1.62; P ,
.001), and having bowel disease (OR, 1.25; 95%CI, 1.09 to
1.43; P = .001).
Barriers to Seeking Medical Advice
Overall, emotional barriers were the most commonly re-
ported barriers to seekingmedical help, with feeling worried
about what a doctor might ﬁnd as the most common barrier
(n = 1,522; 49.4%; Table 5). This was also found among
adults (n = 773; 49.0%) and females (n = 859; 53.2%).
However, insecurity in talking about CRC symptoms with
a doctor was the most frequent barrier among adolescents
(n = 777; 51.7%) and males (n = 752; 51.3%). Tables 6
and 7 list the relationships between recognizing CRC
symptoms and risk factors and reporting a barrier to
seeking medical advice.
DISCUSSION
CRC awareness in Gaza was found to be low. Adults dis-
played higher awareness than adolescents, and females
demonstrated better knowledge than males. Emotional
barriers were most commonly reported among the different
groups. Insecurity in talking about CRC symptoms with
a doctor was the most frequent barrier among adolescents
andmales, and concern about what a doctor might ﬁnd was
the most frequent barrier among adults and females.
The higher level of CRC awareness among women in this
study is consistent with ﬁndings from previous studies.18-20
Women are in contact with health care services more often
than men as a result of pregnancy, family planning, and
childcare, and this might promote their health-related
knowledge and encourage them to have more protective
behaviors than men.21
Similar to other studies,18,19 adults in this study displayed
a better awareness than adolescents. A reason for this may
be higher education levels achieved by adults and expe-
riences enabling them to recognize CRC signs and
symptoms. Another factor could be that adults were
recruited from hospitals and displayed a degree of health-
seeking behavior, which might contribute to their greater
knowledge.11,22 Therefore, targeting young people with
educational interventions on modiﬁable risk factors and
alarming symptoms could be especially beneﬁcial. Pre-
vious studies conducted in Britain and Jordan found similar
low cancer awareness among university students and
adolescents.11,23 Kyle et al24 reported that a school-based
educational intervention program was effective in sus-
tainably raising cancer awareness among adolescents.
Therefore, cancer awareness—especially of common
cancers like CRC—should receive more attention in the
school curriculum, because it could have a potential life-
long effect on encouraging early diagnosis.11,23 In addition,
Power and Wardle25 showed that awareness campaigns
targeting adults could increase their awareness of CRC
symptoms, thus reducing their time to seekmedical advice.
The lack of recognizing CRC symptoms in 51.9% of par-
ticipants in this study is comparable to ﬁndings from other
Arab countries, with 59.0% of Lebanese participants dis-
playing poor knowledge,26 41.0% of participants displaying
poor knowledge about CRC symptoms in Bahrain,16 2.8%
of participants in Saudi Arabia correctly recognizing CRC
symptoms,27 and 14.3% of Jordanian university students
displaying poor knowledge.11 This demonstrates poor
TABLE 2. The Association of Age Group and Sex With Recalling and Recognizing Colorectal Cancer Symptoms
Symptom/Sign
Recall (N = 3,080) Recognition (N = 3,080)
Female Sex Being Adult Female Sex Being Adult
Adjusted OR (95% CI)* P
Adjusted OR
(95% CI)† P
Adjusted OR
(95% CI)* P
Adjusted OR
(95% CI)† P
Abdominal pain 1.04 (0.89 to 1.20) .64 0.79 (0.69 to 0.92) .002 1.11 (0.96 to 1.29) .16 1.24 (1.08 to 1.44) .003
Change in bowel habit 1.16 (0.99 to 1.37) .07 1.66 (1.41 to 1.95) , .001 1.18 (1.03 to 1.37) .020 1.66 (1.44 to 1.92) , .001
Bowel not emptying 0.74 (0.47 to 1.17) .20 2.03 (1.25 to 3.28) .004 1.03 (0.89 to 1.20) .67 1.68 (1.45 to 1.95) , .001
Blood in stools 1.10 (0.88 to 1.39) .39 3.05 (2.38 to 3.92) , .001 1.07 (0.92 to 1.23) .37 1.95 (1.69 to 2.25) , .001
Anorectal bleeding 1.03 (0.77 to 1.37) .89 4.32 (3.02 to 6.17) ,.001 1.27 (1.10 to 1.47) .001 1.73 (1.49 to 1.99) , .001
Anorectal pain 0.43 (0.29 to 0.64) , .001 1.27 (0.87 to 1.85) .22 0.96 (0.82 to 1.11) .56 1.45 (1.25 to 1.68) , .001
Abdominal mass 1.19 (0.95 to 1.49) .13 1.10 (0.88 to 1.38) .40 1.44 (1.24 to 1.66) , .001 1.75 (1.51 to 2.02) , .001
Weight loss 1.26 (0.98 to 1.62) .06 1.92 (1.49 to 2.48) , .001 1.19 (1.03 to 1.37) .020 2.01 (1.74 to 2.32) , .001
Pallor/tiredness 1.05 (0.73 to 1.52) .80 1.65 (1.13 to 2.41) .009 0.99 (0.86 to 1.15) .94 1.79 (1.55 to 2.07) , .001
Abbreviation: OR, odds ratio.
*Adjusted for age group.
†Adjusted for sex.
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knowledge of CRC symptoms in the region, which might be
further compounded by a culture of not talking about
symptoms that might be perceived as embarrassing, and
this assumption is supported by the large proportion of
participants reporting embarrassment as a main barrier in
this study.
Abdominal pain was the most commonly recognized
symptom, as in other studies, which could be attributed to
its interference with daily activities.11,23,28 However, pallor/
fatigability was the most recognized symptom in an Omani
study,15 with 55.1% recognizing the symptom compared
with 40.4% in Gaza. This difference could be caused by the
comparably high prevalence of anemia in Gaza, with rates
of 60.3% in patients with heart disease,29 35.8% among
female adolescents,30 and 33.1% among pregnant
women,31 indicating that anemia is not normally recognized
as a CRC sign.32
Recognition of blood in stools as a CRC symptom by 53.2%
in this study was comparable to 53.0% in the Omani
study,15 50.1% of the Jordanian undergraduate students,11
and more than the 22.5% reported in a Spanish study.33
This underlines the ﬁnding that people in Gaza are more
alarmed by the obvious symptoms and signs of CRC,
whereas common symptoms, such as pallor, and common
deﬁciencies, such as anemia, are not always regarded as
abnormal or unusual.
Al-Azri et al15 reported a higher recognition among Omani
participants than among those from Gaza for CRC risk
factors, such as doing less physical exercise (37.3% v 29.
8%), having a relative with CRC (32.7% v 29.3%), and
diabetes (24.9% v 19.2%). However, Gazans identiﬁed the
low-ﬁber diet more frequently (42.5%) than people in
Oman (38.7%) and Spain (29.5%).15,33
The Omani participants reported a mixture of practical and
emotional barriers as the most common barriers to seeking
medical advice for CRC.15 However, despite the poor
economic circumstances in Gaza, emotional barriers were
most commonly reported, not service or practical barriers,
as would be expected, and higher percentages were ob-
tained especially among females. A possible explanation for
this could be that women tend to display a fear of cancer,
denial, and reliance on alternative therapies.23,34,35 The
lack of female oncologists and surgical specialists in Gaza
could be another reason, especially in the younger age
groups, as found by Elshami et al,10 where feeling
embarrassed was the most common barrier to seeing
a doctor by female adolescents. This was also observed
among American women who reported delays in seeking
care due to a perceived lack of female clinicians.36 How-
ever, a study on CRC screening in theWest Bank, Palestine,
showed similar rates of embarrassment among men and
women,22 which were also signiﬁcantly lower, at 11.0% and
11.4%, than those in this study, at 41.3% and 50.2%,
respectively. Higher numbers of female doctors and cul-
tural differences might be the reason. This demonstrates
the urgent need for more female surgeons and oncologists
in Gaza. In addition, men and adolescents in Gaza did not
feel conﬁdent talking about their symptoms to the doctor,
reﬂecting poor doctor-patient relationships and leading to
additional delays in presentation. Poor communication
skills by health care professionals have also been shown to
affect health care services in other studies from Gaza.10,37
Therefore, it is essential to systematically include com-
munication skills and professionalism in undergraduate
and postgraduate training in Gaza to make services more
accessible, especially to younger people.
The strengths of this study are the large sample size, the
high response rate, and the use of a validated instrument,
the BoCAM. In addition, the inclusion of both adults and
adolescents provides the opportunity for additional rec-
ommendations on prevention interventions.
Limitations of this study include the lack of sociodemo-
graphic data, such as level of education, that can inﬂuence
the awareness of CRC. In addition, no additional exploration
was performed on how much impact factors such as family
history of CRC and familiarity with the disease through
friends and neighbors had on participants’ knowledge of
the disease. Moreover, recruitment of adult participants
from hospitals might have caused a degree of selection bias
because they displayed health-seeking behavior, which
adolescents, recruited from schools, did not.
In conclusion, poor public awareness of CRC symptoms
was demonstrated, especially if symptoms were not af-
fecting daily activities. In addition, the potential impact of
some modiﬁable risk factors (such as obesity, lack of
physical exercise, and Western diet) on increasing the risk
of CRC was poorly understood. Interventions to improve
public awareness of CRC, such as educational in-
terventions in schools and the public domain, are war-
ranted and should be tailored to each age group. Emotional
barriers, especially among women, should be addressed by
training more female clinicians and improving communi-
cation skills of existing physicians. Finally, a strategy to
establish a CRC screening program in Gaza should be
developed to facilitate early detection of CRC in the face of
its increasing incidence.
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